DOI:
10.1055/s-00000105
Zentralblatt für Gynäkologie
LinksClose Window
References
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol 2001; 19: 3808-3816
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.